HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.61
Index: ASX200 | ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.38

14 Apr
2025

-0.020

OPEN

$1.41

-1.43%

HIGH

$1.43

943,869

LOW

$1.38

TARGET
$1.257 -8.9% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 97.9 - 3.3 xxx
DPS (cps) xxx 0.0 13.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 9.7% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-97.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,746.2 M
Book Value Per Share xxxxxxxxxxxxxxx143.3
Net Operating Cash Flow xxxxxxxxxxxxxxx237.8 M
Net Profit Margin xxxxxxxxxxxxxxx-36.42 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-49.94 %
Return on Invested Capital xxxxxxxxxxxxxxx-23.66 %
Return on Assets xxxxxxxxxxxxxxx-19.17 %
Return on Equity xxxxxxxxxxxxxxx-49.94 %
Return on Total Capital xxxxxxxxxxxxxxx2.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx186.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx271 M
Long Term Debt xxxxxxxxxxxxxxx1,327 M
Total Debt xxxxxxxxxxxxxxx1,598 M
Goodwill - Gross xxxxxxxxxxxxxxx1,297 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx60 M
Price To Book Value xxxxxxxxxxxxxxx1.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx64.0 M
Capex % of Sales xxxxxxxxxxxxxxx3.67 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,416 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx265 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx3 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

28/03/2025

-1

No Rating

-1.43%

Ord Minnett highlights Healius' strategy to achieve a high single-digit group EBIT margin by 2027, supported by a cost-out program and operational efficiencies following the sale of its Lumus imaging division.

The company has announced a fully franked special dividend of 41.3c per share, funded from $800m in net proceeds from the $965m Lumus sale, with the remainder used to maintain a net cash position.

Healius targets -$15-20m in annual savings through reduced corporate costs, streamlined pathology operations, and automation, with group earnings forecast to reach $133m by FY27, observes the analyst.

The company expects revenue to grow by 6%, though the broker suspects margin recovery may be challenging given potential cuts to Medicare rebates for Vitamin B12 and mid-stream urine testing.

Sell rating. Target 94 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

5

xx-xxxxxxxxxx xx xxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

31/03/2025

4

Underweight

$1.35

-2.17%

Jarden notes Healius has outlined an ambitious plan to lift EBIT margins to the high single digits by FY27, despite starting from just 0.6% in 1H25.

Management detailed $31m in initiatives, but Jarden remains cautious, forecasting only a 4% margin by FY27 and pointing to funding cuts and execution risk.

Medicare rebates for key pathology tests are set to halve from July, while any volume uplift from bulk billing incentives may take time to flow through.

The Lumus sale, now scheduled for May, will fund a fully franked 41.3c special dividend and debt refinancing. Jarden lifts its target price to $1.35 from $1.18 and maintains an underweight rating.

FORECAST
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.10 cents.
Jarden forecasts a full year FY26 dividend of 1.40 cents and EPS of 2.10 cents.
Access Extra Coverage Research History >

HLS STOCK CHART

FNArena News on HLS

1
Australian Broker Call *Extra* Edition – Apr 14, 2025

Apr 14 2025 - Daily Market Reports
2
In Brief: Tariffs, Healthcare & Wealth Platforms

Apr 11 2025 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Mar 31, 2025

Mar 31 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 03, 2025

Mar 03 2025 - Daily Market Reports
5
FNArena Corporate Results Monitor – 24-02-2025

Feb 24 2025 - Australia

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps